Friday, May 27, 2011

MAP Pharmaceuticals submits LEVADEX NDA to FDA for treatment of migraine in adults


Levadex is designed to be differentiated from existing migraine treatments. It is a novel formulation of dihydroergotamine (see above structure, DHE), a drug used intravenously in clinical settings to effectively and safely treat migraines.
 MAP Pharmaceuticals submits LEVADEX NDA to FDA for treatment of migraine in adults

No comments:

Post a Comment